JOONGHUN-PHARMACEUTICAL
30.3.2021 11:02:14 CEST | Business Wire | Press release
Joonghun Pharmaceutical has officially launched their premium cross-linked hyaluronic acid dermal filler, Artgaon.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210330005456/en/
Artgaon, with its certification of the CE mark, is specifically aimed to target the European aesthetic market as its slogan states “The Finest, for European Professionals”. Joonghun Pharmaceutical is a pharmaceutical company in South Korea that specializes in Hyaluronic Acid Injections used in orthopedic treatments for 15 years. With their in-depth knowledge of HA characteristics, they were able to develop a dermal filler designed to compete against the top European brands in the aesthetics industry.
According to Dr. YeoHye Yoon, the Quality Director from Joonghun, the main vision for Artgaon during its product development was to provide a new aesthetic experience like no other for both the patient and practitioner. To deliver this experience, Artgaon was focused on two things: high quality and unique cross-linking technology.
Artgaon is manufactured under strict pharmaceutical guidelines despite dermal fillers being classified as medical devices. “This commitment enables us to have higher standards of safety for every component of the filler. For example, Artgaon is manufactured in cleanrooms that control particles as small as 10-micrometers. Naturally, this makes Artgaon extremely clean, which we believe would add to the confidence of doctors using our product.”
Artgaon’s unique cross-linking technology allows doctors to enjoy an injection force of a mere 7-8 newtons that is smooth and consistent. Despite this, Artgaon boasts high elastic (G prime) and cohesive properties when inside the skin. Joonghun claims that their formula for Artgaon shows natural results not only by looks but by experiences felt by patients as well. “Artgaon really allows the doctor to mold the beauty they want for their patients due to the low injection force coupled with high molding capabilities.”
The gel characteristics of Artgaon is to be expressed in their soon to be updated package designs. “Artgaon’s new package designs are based on the architectural structure of the industrial era, which remain firm and capture beauty even to this day. We wanted this architectural beauty from the industrial era to represent Artgaon’s gel structure; to be firm and attain its beauty even over time.”
The quality and performance of Artgaon has already surprised doctors who have tested Artgaon. It is only a matter of time until Artgaon disrupts the beauty market of Europe and the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005456/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom